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Abstract
Background: Mice lacking Receptor-interacting protein 140 (RIP140) have reduced body fat which at least partly is
mediated through increased lipid and glucose metabolism in adipose tissue. In humans, RIP140 is lower expressed
in visceral white adipose tissue (WAT) of obese versus lean subjects. We investigated the role of RIP140 in human
subcutaneous WAT, which is the major fat depot of the body.
Methods: Messenger RNA levels of RIP140 were measured in samples of subcutaneous WAT from women with a
wide variation in BMI and in different human WAT preparations. RIP140 mRNA was knocked down with siRNA in in
vitro differentiated adipocytes and the impact on glucose transport and mRNA levels of target genes determined.
Results: RIP140 mRNA levels in subcutaneous WAT were decreased among obese compared to lean women and
increased by weight-loss, but did not associate with mitochondrial DNA copy number. RIP140 expression increased
during adipocyte differentiation in vitro and was higher in isolated adipocytes compared to corresponding pieces
of WAT. Knock down of RIP140 increased basal glucose transport and mRNA levels of glucose transporter 4 and
uncoupling protein-1.
Conclusions: Human RIP140 inhibits glucose uptake and the expression of genes promoting energy expenditure in
the same fashion as the murine orthologue. Increased levels of human RIP140 in subcutaneous WAT of lean
subjects may contribute to economize on energy stores. By contrast, the function and expression pattern does not
support that RIP140 regulate human obesity.
Background
Adipose tissue has a central role in regulating energy
homeostasis. Maintenance of energy balance requires
tightly regulated expression of gene networks that con-
trol metabolic functions in response to changing envir-
onmental conditions [1,2].
Receptor-interacting protein 140 (RIP140) is a nuclear
receptor corepressor that in mice is expressed in several
organs; however the mRNA levels in white adipose tis-
sue (WAT) are higher than in other metabolically active
tissues, such as brown adipose tissue (BAT), muscle,
and liver [3-5]. The physiological function of RIP140 has
been tested in RIP140 knock out (RIPKO) mice. These
mice have a reduced body weight and body fat content,
when compared to wild-type (WT) mice [3]. The lean
phenotype of RIPKO mice is not explained by impaired
adipogenesis, since RIP140 is not required for adipocyte
differentiation [3]. Furthermore, RIPKO mice exhibit
increased oxygen consumption, total fatty acid oxida-
tion, glucose tolerance, insulin responsiveness upon
high-fat feeding, and resistance to high-fat diet-induced
obesity [3,5]. At the cellular level several genes, includ-
ing cell death-inducing DFFA-like effector a (CIDEA),
uncoupling protein-1 (UCP-1), and glucose transporter 4
(GLUT4) are upregulated in adipocytes from RIPKO as
compared to WT-mice. Thus in mice RIP140 seems to
play an important role in energy homeostasis which at
least in part can be explained by its action on glucose
uptake as well as lipid metabolism in white fat cells.
Surprisingly few studies have examined the expression
of RIP140 expression in human organs. We therefore
searched the GEO profiles database http://www.ncbi.
nlm.nih.gov/ for RIP140 mRNA expression in the
human transcriptome. According to record GDS596
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RIP140 mRNA is widely expressed in different human
tissues with particularly high expression levels observed
in lung, skeletal muscle, reproductive organs and brain.
It has recently been reported that RIP140 mRNA and
protein levels are decreased in visceral WAT of mor-
bidly obese as compared to lean humans implying that
human RIP140 may, just as its rodent orthologue, regu-
late adipose tissue metabolism [6]. However, the func-
tion and expression of RIP140 mRNA in human
subcutaneous WAT, which comprises the main store of
body fat, has to our knowledge not been reported.
Caution should be exercised when extrapolating data
from mice to man when adipose tissue is compared. For
example there are major species differences in the regu-
lation of lipid metabolism in fat cells [7]. This study was
conducted with the aim of elucidating if RIP140 might
be involved in the regulation of the subcutaneous fat
mass in humans and if RIP140 had similar function in
human white fat cells as in murine adipocytes. To
accomplish this we investigated if RIP140 was present in
human white fat cells and related the expression of
RIP140 in human subcutaneous WAT to adiposity. In
order to mimic the effect of gene knock out in mice we
silenced RIP140 expression in human in vitro differen-
tiated adipocytes and analyzed the effects of decreased
mRNA levels of RIP140 on glucose transport and a set
of genes involved in the control of energy homeostasis.
Methods
Subjects were recruited by local advertisement for the
purpose of studying genes regulating obesity and fat cell
function. Obesity was defined as having a BMI ≥ 30 kg/
m2, whereas leanness was defined as having a BMI ≤ 25
kg/m2. Informed consent was received from all subjects
involved in the study. The project was conducted in
accordance with the guidelines in The Declaration of
Helsinki and approved by the ethical committee at Kar-
olinska University Hospital.
Paired samples of omental and abdominal subcuta-
neous WAT for mRNA measurements were available in
cohort 1 comprising lean (N = 11; age 40 ± 14 years;
BMI 24 ± 2 kg/m2) and obese (N = 22; age 43 ± 9
years; BMI 44 ± 4 kg/m2) women. The non-obese sub-
jects were operated for uncomplicated gallstone disease
and the obese with anti-obesity surgery as described
previously [8]. These patients had been fasting overnight
and only saline was given as an intravenous infusion
until adipose tissue was removed [8].
Subcutaneous abdominal WAT biopsies for mRNA
measurements were available from cohorts 2 and 3.
WAT (0.5-2 g) were obtained in the morning after an
overnight fast from needle biopsies under local anesthe-
sia as described previously [9]. Cohort 2 (N = 10
women; age 39 ± 6 years; BMI 40 ± 6 kg/m2) were
investigated before and after (1.5-4 years) weight reduc-
tion induced by intense anti-obesity therapy with anti-
obesity surgery or behavioral modification. All subjects
became non-obese and were reinvestigated when they
were weight-stable. These subjects have been described
before [10]. Cohort 3 comprised 34 women with a wide
variation in BMI (N = 34; age 42 ± 12 years; BMI 30 ±
7 kg/m2) for which relative amounts of mitochondrial
DNA (mtDNA) to nuclear DNA in subcutaneous WAT
were determined by quantitative RT-PCR. To investigate
if RIP140 levels differed between genders we investigated
three men before (age 37 ± 11 years; BMI 38 ± 3 kg/m2)
and after the anti-obesity treatment described above
under cohort 2.
For the following adipocyte studies abdominal subcu-
taneous adipose tissue pieces were obtained as a waste
product from plastic surgery. There was no selection on
the basis of body fat content. WAT pieces were treated
with collagenase as described elsewhere for isolation of
the fat cells and the stroma vascular fraction, respec-
tively [11]. Paired samples of isolated adipocytes and
corresponding bits of subcutaneous WAT were available
from five obese and five lean women (age 43 ± 14; BMI
28 ± 6 kg/m2). Cells harvested from the stroma vascular
fraction were in vitro differentiated to adipocytes
according to a method described previously [11]. RIP140
mRNA was quantified at day 4th, 8th, and 12th of differ-
entiation in primary adipocyte cultures from eight
women (age 46 ± 13 years; BMI 27 ± 6 kg/m2). in vitro
differentiated adipocytes were prepared from five
women (age 44 ± 13 years; BMI 26 ± 2 kg/m2) for
siRNA and glucose transport experiments. RIP140 pro-
tein was detected in subcutaneous WAT from five
women (age 32 ± 4 years; BMI 24 ± 8 kg/m2).
WAT samples were brought to the laboratory in saline
and either used immediately for in vitro studies or fro-
zen in liquid nitrogen, and stored at -70°C until mRNA,
DNA, and/or protein measurements were performed.
Quantification of mitochondrial DNA copy number
The ratio of mtDNA to nuclear DNA reflects the tis-
sue concentration of mtDNA per cell and was deter-
mined by quantitative RT-qPCR as described. Briefly, a
120 nucleotide-long mtDNA fragment within the mito-
chondrial NADH dehydrogenase subunit 1 (ND1) gene
was used for quantification of mtDNA. The PCR frag-
ment has previously been cloned into a plasmid. Plas-
mid standards of known copy number were used to
generate a log-linear standard curve, from which the
ND1 copy numbers of studied samples could be deter-
mined by RT-qPCR. A 120 bp region of the nuclear
gene lipoprotein lipase (LPL) was used to normalize
results. Plasmid standard curves containing the LPL
fragment were used to determine cell number of stu-
died samples [12,13].
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Protein expression
Approximately 300 mg of subcutaneous WAT was lysed
in 600 μl protein lysis buffer (1% Triton-X 100, Tris-
HCl pH 7.6 and 150 mmol/L NaCl, 4°C), supplemented
with protease inhibitors (1 mmol/L phenylmethylsulfo-
nyl fluoride and Complete® (Boehringer, Mannheim,
Germany)), and homogenized. The lysed tissue was cen-
trifuged at 14 000 RPM for 30 minutes after which the
infranatant was collected. Protein content was assayed
spectrophotometrically using the BCA Protein Assay
Reagent Kit (PIERCE, Rockford, IL) on 96-well microti-
ter plates with bovine serum albumin (BSA) (SIGMA, St
Louis, MO) as standard. To test if proteins remained in
the fat cake following protein extraction the fat cake
was removed and subjected to methanol-chloroform
(Merck, Darmstadt, Germany) extraction which effec-
tively collects all proteins [14]. These extracted proteins
were dissolved in 600 μl protein lysis buffer (same as
above). Protein levels in fat cake extracts were below the
detection limit. After optimization the following condi-
tions were chosen. 100 mg of total cellular protein was
loaded on polyacrylamide gels and separated by standard
10% sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis. Preadipocytes were used as a negative con-
trol since RIP140 expression is induced in later stages of
differentiation. Gels were transferred to polyvinylidine
fluoride membranes (Amersham Biosciences, Little
Chalfont, UK). For RIP140 detection the blot was
blocked for 1 h at room temperature in Tris-buffered
saline with 0.1% Tween-20 (TBS-T) and 3% BSA
(SIGMA). This was followed by an overnight incubation
at 4°C in the presence of 4 μg/ml antibody directed
against RIP140 (R 5027, SIGMA). The following day the
membrane was rinsed in TBS-T and secondary a-rabbit
antibodies conjugated to horseradish peroxidase
(SIGMA) were added. The membrane was incubated in
room temperature for one hour and after that rinsed
with TBS-T. Antigen-antibody complexes were detected
by chemiluminescence using a kit from LumiGLO® (Cell
Signaling Technology, Danvers, MA) and specific bands
were detected using a Chemidoc XRS system (Bio-Rad
Laboratories Inc., Hercules, CA).
Small interfering RNA mediated knock down
Cells harvested from the stroma vascular fraction
obtained after collagenase treatment of subcutaneous
WAT were in vitro differentiated to adipocytes accord-
ing to a method described previously [11] and treated
with siRNA as described [15]. Briefly, 200 000 cells/well
were seeded in a 12-well plate and in vitro differentiated
for twelve days at 37°C in 5% CO2. On the tenth day of
differentiation cells were treated with 100 nM ON-TAR-
GETplus SMARTpool RIP140 (L-006686-00) small
interfering RNA (siRNA) (Thermo Fisher Scientific,
Lafayette, CO) and 9 μl HiPerFect Transfection Reagent
(Qiagen, Hilden, Germany) according to the manufac-
turer’s protocols. These conditions were chosen after
careful optimization. To control for unspecific effects of
siRNA treatment, control cells were treated with All-
Stars Negative Control siRNA (Qiagen). After 48 hours
cells were lysed for isolation of RNA using 350 μl lysis
buffer containing RA1 lysis buffer (Macherey-Nagel,
Duren, Germany) and 3.5 μl b-mercaptoethanol.
Glucose uptake
In vitro differentiated human adipocytes were treated
with RIP140 or non-silencing siRNA as described above.
48 hours post transfection cells were washed with glu-
cose-free DMEM (Biochrom, Berlin, Germany) and
incubated at 37°C for three hours in medium consisting
of 1:1 glucose-free DMEM and HAM/F12 (Gibco, Invi-
trogen, Carlsbad, CA). To determine net insulin effect
on glucose transport, insulin was added to cells at a
final concentration of 10-6 M followed by incubation at
37°C for 15 minutes. One μCi of 2-Deoxy-D- [1-3H]
glucose (Amersham Biosciences) per 1 ml medium was
added to the cells followed by 20 minutes incubation at
37°C. Cells were washed in ice cold PBS, lysed in 0.1%
SDS-H2O, and radioactivity was measured in liquid scin-
tillant in a b-counter 1214 Rackbeta LKB (Wallac, Perki-
nElmer Life Sciences, Waltham, MA) the following day.
RNA preparation
Total RNA was extracted from isolated adipocytes (200
μl) and corresponding pieces of subcutaneous WAT
(300 mg), as well as in vitro differentiated adipocytes
(200 μl) using the NucleoSpin® RNA II (Macherey-
Nagel) kit. RNA concentration and purity was measured
spectrophotometrically using a Nanodrop ND-1000
Spectrophotometer (Thermo Fisher Scientific). Half a
microgram of total RNA was reverse transcribed using
Omniscript First-strand cDNA synthesis kit (Qiagen)
and random hexamer primers (Invitrogen). RNA puri-
fied from in vitro differentiated adipocytes were reversed
transcribed using iScript™ cDNA synthesis kit (Bio-Rad
Laboratories Inc.), with some modifications. Purified
total RNA, RNase-free water, and 5× iScript reaction
mixes were preheated for 15 minutes at 55°C. After pre-
heating tubes were put on ice for one minute and
iScript reverse transcriptase was added.
Quantitative real time PCR
For TaqMan assays 10 ng of cDNA was mixed with 2×
TaqMan Universal PCR Master Mix (Applied Biosys-
tems, Foster City, CA) and TaqMan@ Gene Expression
Assays (Applied Biosystems) in a final volume of 20 μl.
mRNA was analyzed for RIP140 (Hs00942766_s1), glu-
cose transporter 1 (GLUT1) (Hs00197884_m1), GLUT4
(Hs00168966_m1), CIDEA (Hs00154455_m1), UCP-1
(Hs00222453_m1), PPARg co-activator 1a (PGC-1a)
(Hs00173304_m1), low density lipoprotein receptor-
related protein 10 (LRP10) (Hs00204094_m1), and 18S
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(Hs99999901_s1). For SYBR Green assays, 5 ng of
cDNA was mixed with 2× iQ SYBR Green Supermix
(Eurogentec S.A., Ougrée, Belgium) and primers (Invi-
trogen) in a final volume of 25 μl. Primer pairs were
designed to span exon-intron boundaries and to be spe-
cific for the mRNA to be amplified according to BLAST
searches. The following primers were used for specific
mRNA quantification: RIP140 (forward primer 5’-TGA
CCA AAA CCA ACC CAA TAC T-3’, reverse primer
5’-GAC CTG TGA GAC ACT TTC AGC A-3’), PPARg
(forward primer 5’-ACA AGG CCA TTT TCT CAA
ACG-3’, reverse primer 5’-CGG AGA GAT CCA CGG
AGC-3’), hormone-sensitive lipase (HSL) (forward primer
5’-GGA AGT GCT ATC GTC TCT GG-3’, reverse pri-
mer 5’-GGC AGT CAG TGG CAT CTC-3’), LRP10
(forward primer 5’-GAT GGA GGC TGA GAT TGT
G-3’, reverse primer 5’-GAG TCA TAT CCT GGC
GTA AG-3’), and 18S (forward primer 5’-TGA CTC
AAC ACG GGA AAC C-3’, reverse primer 5’-TCG
CTC CAC CAA CTA AGA AC-3’). Dissociation curve
analyses and agarose gel electrophoresis were used to
validate that one single amplicon was amplified. Quanti-
tative real-time PCR was performed using an iCycler
IQ™ (Bio-Rad Laboratories Inc.). PCR efficiency in all
runs was close to 100% and samples were run in dupli-
cate. Expression of mRNA was normalized to an inter-
nal reference gene, 18S (isolated adipocytes and
corresponding bits of subcutaneous WAT) or LRP-10
(in vitro differentiated adipocytes) by using a compara-
tive Ct method, i.e. 2ΔCt-target gene/2ΔCt-reference gene. The
patient with the highest Ct value for the target gene was
used as a calibrator from which all other Ct values for
the target gene and reference gene, respectively, were
subtracted.
Statistical analysis
The mRNA levels between two groups were compared
with paired Student’s t-test. When comparing three
groups, results were evaluated with ANOVA. Correla-
tion between RIP140 mRNA levels and mtDNA copy
number was studied with multiple regression analysis
with age and BMI as covariate. If necessary, RIP140
levels were log10-transformed to become normally dis-
tributed. Values were presented as mean ± SD. All sta-
tistics were calculated with Statview (version 5.01, SAS
Institute, Cary, NC).
Results
Subcutaneous WAT RIP140 mRNA levels are inversely
correlated to obesity
We first assessed abdominal subcutaneous WAT RIP140
mRNA levels in relationship to adiposity. RIP140 mRNA
levels were decreased approximately 50% in obese com-
pared to lean women in subcutaneous WAT (cohort 1,
P < 0.001) (Figure 1A). We also confirmed decreased
levels (25%) of RIP140 mRNA in visceral WAT of obese
subjects (cohort 1, P < 0.01) (Figure 1A). Levels of
RIP140 mRNA were lower in visceral as compared to
subcutaneous WAT, and this was due to a difference in
lean subjects only (Figure 1A). No difference between
WAT depots were observed in obese subjects. Expres-
sion of RIP140 mRNA in subcutaneous WAT increased
2.5-fold after long term weight-loss to a weight-stable,
lean state (cohort 2, P < 0.01) (Figure 1B). There was no
difference in RIP140 mRNA expression between genders
before (women 0.11 ± 0.34 vs. men 0.09 ± 0.13 log10
AU) or after (women 0.42 ± 0.10 vs. men 0.30 ± 0.12
log10 AU) weight-loss.
Considering that RIP140 has been implicated in regu-
lation of energy expenditure and mitochondrial function
in mice, we related subcutaneous WAT RIP140 mRNA
levels to mtDNA copy number, which is a simple mea-
sure of mitochondrial mass that can be used to screen
mitochondrial content in a large number of samples
[5,13]. RIP140 mRNA levels in subcutaneous WAT did
not associate with mtDNA copy number in 34 investi-
gated women (results not shown).
RIP140 mRNA and protein in WAT
We next evaluated the distribution of RIP140 in subcu-
taneous WAT. RIP140 mRNA expression was increased
almost twofold in isolated adipocytes compared to cor-
responding intact pieces of WAT (P < 0.001) (Figure
2A). Furthermore, obesity was associated with reduced
levels of RIP140 mRNA in adipocytes (obese N = 5, 0.87
± 0.12 log10 AU vs. lean N = 5, 1.12 ± 0.10 log10 AU, P
> 0.01). During in vitro human adipocyte differentiation
RIP140 levels were up-regulated during the 8th and 12th
day compared to the 4th day of differentiation (P <
0.001 for both). There was no significant change in
expression when comparing the 8th and 12th day (Figure
2B). RIP140 protein was detected by western blot analy-
sis in subcutaneous WAT with preadipocytes as a nega-
tive control (Figure 3).
RIP140 knock down increases glucose uptake and
expression of UCP-1 and GLUT4
To elucidate the biological role of RIP140 we silenced
RIP140 in in vitro differentiated human adipocytes by
siRNA. Depletion of RIP140 mRNA levels was con-
firmed by real-time PCR to be significantly knocked
down by ~80% (p < 0.01) (Figure 4A). We then investi-
gated how this knock down affected glucose transport
and mRNA levels for a set of genes involved in glucose
metabolism and energy expenditure. Basal glucose trans-
port was significantly up regulated in RIP140 knock
down adipocytes compared to cells transfected with
non-silencing siRNA (p < 0.05), while the net insulin
effect was unaffected (Figure 4B). In general, insulin-sti-
mulated glucose uptake was significantly higher than
basal glucose uptake in non-silencing as well as RIP140
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siRNA transfected cells and individuals with high basal
glucose uptake had high insulin stimulated glucose
uptake.
RIP140 silencing significantly increased mRNA levels
of GLUT4 and UCP-1 compared to control cells (P <
0.01 for both) (Figure 4C). Fold change vs. non-silencing
control siRNA was for GLUT4 7.2 ± 1.7 and for UCP-1
32.2 ± 14.5. A trend toward increased mRNA levels for
GLUT1 and CIDEA was observed (P = 0.0594 and P =
0.052, respectively). Fold change vs. non-silencing
control siRNA was for GLUT1 2.1 ± 1.0 and for CIDEA
3.5 ± 2.2. In contrast, PGC-1a, PPARg, and HSL mRNA
levels remained unchanged (Figure 4C).
Discussion
To the best of our knowledge this is the first study
investigating the function of RIP140 in human subcuta-
neous WAT, which is the major fat depot of the body.
In mice it appears that the RIP140 is involved in glucose
metabolism and energy expenditure of WAT [3-5,16,17].
Figure 1 RIP140 mRNA expression in human WAT and obesity. A) RIP140 mRNA levels were measured in omental and subcutaneous WAT
from 22 obese and 11 lean women. B) Subcutaneous WAT RIP140 mRNA levels were investigated before and after weight-loss to a weight-
stable non-obese state (subjects, N = 10). All samples were run in duplicate and normalized to the reference gene 18S. Arbitrary units (a.u.) are
presented as mean ± standard deviation and were log10-transformed to become normally distributed. **, P < 0.01 and ***, P < 0.001.
Figure 2 Localization of human RIP140 in WAT. A) RIP140 mRNA levels were measured in isolated adipocytes and corresponding bits of
subcutaneous WAT from ten women. B) RIP140 mRNA expression was quantified at the 4th, 8th, and 12th day of adipocyte differentiation in vitro.
RIP140 arbitrary units (a.u.) were calculated as 2ΔCt-target gene/2ΔCt-reference gene using 18S (isolated adipocytes and corresponding WAT) and LRP10
(cultured adipocytes) as reference genes. Values are presented as mean ± SD and were log10-transformed to become normally distributed when
needed. ***, P < 0.001.
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We have shown that RIP140 mRNA levels in subcuta-
neous WAT, as has previously been reported for visceral
WAT [6], are inversely correlated with measures of
adiposity and are enriched in fat cells of adipose tissue.
Moreover, RIP140 reduce basal glucose transport and
expression of the genes GLUT4 and UCP-1.
RIP140 is enriched in isolated fat cells than intact
WAT. This suggests that its major function is confined
to the adipocytes of WAT although a role in stroma
vascular cells is not to be excluded. Furthermore,
human RIP140 mRNA expression increased during adi-
pocyte differentiation, which is in agreement with results
in mice [3-5,18]. Since mouse RIP140 has no impact on
the differentiation process, we focused on the impor-
tance of RIP140 for metabolism in the differentiated
human white fat cells. Silencing of RIP140 increased
basal glucose transport, but had no impact on the effect
of insulin on glucose uptake. In 3T3-L1 adipocytes, inhi-
bition of RIP140 by siRNA has been reported to increase
insulin-stimulated glucose uptake [5]. However, at an
early stage of adipocyte differentiation, basal glucose
uptake was also increased [5]. Furthermore, we observed
that primarily mRNA levels of the glucose transporter
GLUT4 but not GLUT1 were increased by RIP140 silen-
cing in human fat cells, which is in line with data from
knock out mice [5]. An impact on GLUT1 expression
could not be excluded but was marginal compared to
the impact on GLUT4 expression. Thus, it appears that
RIP140 in both human and mice acts as an inhibitor of
glucose uptake although there may be some differences
in the action of insulin on glucose uptake between the
different in vitro cell systems. The mechanisms leading
to increased basal glucose transport in RIP140-depleted
human adipocytes are unknown. Potential mechanisms
involve post-translational effects on GLUT1 protein or
involvement of other GLUT-proteins. Additional experi-
ments are needed to elucidate how RIP140 regulates
basal glucose uptake. Similarly, additional experiments
are necessary to clarify whether GLUT4 is directly regu-
lated by RIP140 and what other transcriptional regula-
tors are involved, or if altered GLUT4 expression is
mediated through changes in adipocyte metabolism. In
3T3-L1 adipocytes, the effects of RIP140 on glucose
uptake are at least partly mediated via the transcription
factor Estrogen-related receptor alpha (ERRa) [5]. ERRa
is an important regulator of genes in energy metabolism
[5]. Loss of ERRa prevents increased GLUT4 expression
and deoxyglucose uptake in RIP140 depleted adipocytes.





Figure 3 Detection of RIP140 protein with Western blot in subcutaneous WAT of five women. Preadipocytes were used as a negative
control (-ctrl).
Figure 4 Effect of RIP140 silencing on human in vitro differentiated adipocytes. A) RIP140 mRNA levels in RIP140 siRNA and non-silencing
siRNA (scramble) treated cells. B) Glucose transport, measured as counts per minute (CPM), was determined 48 hours post siRNA transfection.
Net insulin effect was calculated by subtracting insulin-stimulated glucose uptake with basal glucose uptake. C) Specific mRNA levels were
measured 48 h after siRNA mediated RIP140 knock down. In A and C, values are presented as fold change versus non-silencing siRNA (scramble).
Data presented are mean ± SD of five independent experiments. *, P < 0.05 and **, P < 0.01.
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RIP140 silencing in human in vitro differentiated adi-
pocytes led to increased mRNA levels of UCP-1, but not
PGC-1a, PPARg, and HSL. These results confirm pre-
vious data from knock out mice [3,4]. The up-regulation
of CIDEA expression was non-significant in our study
(P = 0.0525). However, it is quite conceivable that
RIP140 regulates CIDEA expression in human WAT
since our results are in line with previous observations
in mice [3-5]. In a one sided analysis, which is justified
for confirmatory data, CIDEA mRNA levels were
induced significantly by RIP140 silencing (P < 0.05).
Altogether, RIP140 had a smaller impact on CIDEA
mRNA levels in humans as compared to mice. One pos-
sible explanation for this discrepancy is the difference in
CIDEA expression between mice and human. Human
CIDEA is expressed in WAT in contrast to mice where
CIDEA is widely expressed in BAT but most often not
detected in WAT [19-21]. UCP-1 encodes a member of
the mitochondrial proton carrier family of proteins and
is expressed in BAT, but only to a limited extent in
WAT [22]. Elevated UCP-1 levels are thought to convert
WAT towards a browner phenotype by allowing mito-
chondrial respiration to occur in the absence of ATP-
synthesis with dissipation of the produced energy as
heat. CIDEA has also been implicated as a regulator of
energy expenditure in both mice and humans [21,23].
Thus, our results support the notion that inhibition of
human RIP140, similar to the murine homologue,
increases the expression of genes involved in the regula-
tion of energy expenditure. In our study we found no
association between RIP140 mRNA levels and mtDNA
copy number, which is in agreement with a study per-
formed in mice [4]. This together with the elevated
levels of UCP-1 suggests that RIP140 influences the
function of existing mitochondria rather than biogenesis.
As has previously been reported in visceral WAT [6],
abdominal subcutaneous RIP140 mRNA levels were
reduced in obesity. Considering the functions ascribed
to lack of RIP140 in in vitro studies, i.e. increased glu-
cose uptake and elevated energy expenditure, it is diffi-
cult to link reduced RIP140 levels in obesity with a
primary role in adiposity. We therefore consider the
alternative that the physiological role of increased levels
of RIP140 in lean subjects functions to economize on
energy stores more likely. On the other hand, down reg-
ulation of RIP140 in obesity could be accompanied by
changes in expression of other transcription factors and
co-factors, which could lead to a different metabolic
outcome than down regulation of RIP140 in cell
cultures.
Conclusion
In conclusion, in agreement with its mouse homologue
human RIP140 is involved in the control of energy
homeostasis of white fat cells by inhibiting glucose
uptake and genes regulating energy expenditure.
Furthermore, increased RIP140 expression in lean and
after weight reduction may be a mechanism to econo-
mize on energy stores. By contrast, the function and
expression pattern does not support that RIP140 regu-
late human obesity.
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